Arcus Biosciences
RCUS
57 hedge funds and large institutions have $293M invested in Arcus Biosciences in 2018 Q1 according to their latest regulatory filings, with 57 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
46.66% more ownership
Funds ownership: 0% → 46.66% (+47%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Alphabet Inc
Mountain View,
California
|
+$84.1M |
| 2 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
+$57.4M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$37.3M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$35.3M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
+$21.2M |
Top Sellers
RCUS Hedge Fund Activity: Q1 2018 in Review
57 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q1 2018, worth a combined $293M.
Buyers outnumbered sellers: 57 funds opened new RCUS positions and 0 closed out — a net gain of 57 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Alphabet Inc, opening a new position worth an estimated $84.1M.
- 57 institutional investors held Arcus Biosciences (RCUS) as of Q1 2018, up from 0 in Q4 2017.
- Funds reported $293M of Arcus Biosciences stock for Q1 2018.
- 57 funds opened new Arcus Biosciences positions in Q1 2018 and 0 closed out, a net change of +57 holders.
- The largest Arcus Biosciences buyer in Q1 2018 was Alphabet Inc, an estimated $84.1M added.
Based on aggregated 13F filings for Q1 2018.